Shenzhen Salubris Pharmaceuticals Co., Ltd. (SHE:002294)

SHE:002294 Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020
Cash & Equivalents	992.22	1,125	1,322	2,670	3,236	865.13
Short-Term Investments	883.91	988.85	695.51	531.58	-	-
Trading Asset Securities	545.66	733.86	186.06	328.36	60	214.59
Cash & Short-Term Investments	2,422	2,848	2,204	3,530	3,296	1,080
Cash Growth	26.81%	29.25%	-37.58%	7.12%	205.25%	-18.20%
Accounts Receivable	791.23	565.87	545.38	557.72	474.03	526.57
Other Receivables	28.29	23.85	21.01	23.4	155.48	30.63
Receivables	819.51	589.72	566.39	581.12	629.51	557.2
Inventory	523.25	506.76	490.86	543.53	420.45	391.56
Prepaid Expenses	-	-	-	-	-	1.13
Other Current Assets	602.14	80.02	52.43	56.36	58	102.31
Total Current Assets	4,367	4,025	3,313	4,711	4,404	2,132
Property, Plant & Equipment	1,480	1,430	1,457	1,506	1,638	1,507
Long-Term Investments	887.81	1,840	1,701	963.07	854.48	835.67
Goodwill	219.49	10.91	10.91	60.53	87.14	87.14
Other Intangible Assets	1,477	1,335	1,318	965.46	1,048	1,244
Long-Term Deferred Tax Assets	132.9	151.24	87.4	88.42	82.01	98.26
Long-Term Deferred Charges	1,964	1,597	1,416	1,344	1,047	816.84
Other Long-Term Assets	456.56	77.26	93.31	116.64	83.09	197.43
Total Assets	10,984	10,466	9,397	9,755	9,244	6,918
Accounts Payable	158.21	126.09	156.01	219.65	187.67	223.39
Accrued Expenses	229.06	717.67	491.34	558.35	487.02	327.04
Short-Term Debt	214.28	120	40	177.19	63	300.26
Current Portion of Leases	12.04	9.7	10.93	11.46	6.99	-
Current Income Taxes Payable	84.73	7.15	10.49	28.92	37.2	10.7
Current Unearned Revenue	40.15	38.36	29.55	42.66	97.99	53.23
Other Current Liabilities	646.16	94	76.77	565.4	132.98	182.37
Total Current Liabilities	1,385	1,113	815.08	1,604	1,013	1,097
Long-Term Debt	-	-	-	-	-	90
Long-Term Leases	17.03	4.18	12.54	19.58	9.11	-
Long-Term Unearned Revenue	115.49	142.04	84.11	98.53	93.71	89.61
Long-Term Deferred Tax Liabilities	33.26	20.97	13.04	27.18	-	19.82
Other Long-Term Liabilities	502.04	433.14	416.47	29.64	82.57	30.41
Total Liabilities	2,052	1,713	1,341	1,779	1,198	1,327
Common Stock	1,115	1,115	1,115	1,115	1,115	1,046
Additional Paid-In Capital	1,972	1,928	1,900	1,866	1,930	-
Retained Earnings	5,646	5,620	5,564	5,529	5,330	4,798
Treasury Stock	-	-	-602.16	-602.16	-327.86	-327.75
Comprehensive Income & Other	39.76	49.3	42.22	33.24	-13.41	-7.69
Total Common Equity	8,773	8,712	8,019	7,941	8,034	5,508
Minority Interest	159.01	40.17	36.43	35.81	11.91	83.33
Shareholders' Equity	8,932	8,752	8,055	7,977	8,046	5,592
Total Liabilities & Equity	10,984	10,466	9,397	9,755	9,244	6,918
Total Debt	243.35	133.88	63.47	208.23	79.1	390.26
Net Cash (Debt)	2,178	2,714	2,140	3,322	3,217	689.46
Net Cash Growth	18.95%	26.83%	-35.58%	3.28%	366.56%	-29.40%
Net Cash Per Share	1.94	2.44	1.92	3.02	3.01	0.68
Filing Date Shares Outstanding	1,115	1,115	1,091	1,091	1,103	1,029
Total Common Shares Outstanding	1,115	1,115	1,091	1,091	1,103	1,029
Working Capital	2,982	2,912	2,498	3,108	3,391	1,035
Book Value Per Share	7.87	7.81	7.35	7.28	7.29	5.36
Tangible Book Value	7,076	7,366	6,690	6,915	6,898	4,177
Tangible Book Value Per Share	6.35	6.61	6.13	6.34	6.26	4.06
Buildings	-	1,222	1,218	1,208	1,218	946.22
Machinery	-	1,258	1,203	1,138	1,109	923.7
Construction In Progress	-	62.33	34.35	37.6	94.13	343.78

Source: S&P Global Market Intelligence. Standard template. Financial Sources.